Schizophrenia Spectrum and Other Psychotic Disorders clinical trials
The registry lists 84 studies for Schizophrenia Spectrum and Other Psychotic Disorders across more than 10 countries. 14 are recruiting or about to start. 26 of them are mainly about Schizophrenia Spectrum and Other Psychotic Disorders (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 5 narrower conditions too, such as Schizophrenia: 4,163 studies, 636 open.
Get an email when these change. Save the Schizophrenia Spectrum and Other Psychotic Disorders studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Centre for Addiction and Mental Health (4) · University of Minnesota (4) · Fundación Marques de Valdecilla (3) · AbbVie (3) · Massachusetts General Hospital (2) · Karolinska Institutet (2) · National Institute on Drug Abuse (NIDA) (2) · Chinese University of Hong Kong (2)
Who develops what
Save this setEvery programme with a company-led study here in the last two years, whatever its size: 1 programme from 1 company, 0 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.
Comparator & background therapies
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
None given by two companies or more yet.
Programmes
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
The 1 programme — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Primary completion in the next 12 months (0)
Live phase 2 and 3 studies of these programmes. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
None in the next 12 months.
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorised original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licences, line of therapy, academic comparators, sales.
What is being tested here
Drugs under test in Schizophrenia Spectrum and Other Psychotic Disorders studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| ML-007C | 2 | 0 | 2 |
| Tirzepatide | 1 | 0 | 1 |
| Emraclidine | 0 | 0 | 3 |
| Rituximab | 0 | 0 | 2 |
| Risperidone | 0 | 0 | 2 |
| Paliperidone | 0 | 0 | 2 |
| Ziprasidone | 0 | 0 | 2 |
| Cycloserine | 0 | 0 | 2 |
| MK-8189 | 0 | 0 | 1 |
| Vitamin D | 0 | 0 | 1 |
Drug classes tested here Antipsychotics 5
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 6
- Dec 2026Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic · Bjorn H. Ebdrup
- Feb 2027Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia · Central South University
- Mar 2027EPI-MINN: Targeting Cognition and Motivation - National · University of Minnesota
- Jun 2027Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services · Beth Israel Deaconess Medical Center
- Aug 2027REFLECT: A Novel Group-Based Compassion-Focussed Cognitive Behavioural Approach to Core Beliefs in Psychosis · University of Toronto
- Sep 2027SloMo2: Implementation, Effectiveness, and Cost-effectiveness Study · King's College London
Who these studies take
Of the 11 Schizophrenia Spectrum and Other Psychotic Disorders studies recruiting now, 7 (64%) set no upper age limit and 3 (27%) stop at 75 or younger. 1 (9%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (18%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (9%) | 1 (9%) |
| 18 | 10 (91%) | 10 (91%) |
| 30 | 10 (91%) | 10 (91%) |
| 40 | 10 (91%) | 10 (91%) |
| 50 | 8 (73%) | 8 (73%) |
| 65 | 9 (82%) | 9 (82%) |
| 75 | 8 (73%) | 8 (73%) |
| 85 | 8 (73%) | 8 (73%) |
Across all 84 studies, recruiting or not: 70% stop at 75 or younger and 67% at 65; 23% take children; 0% are for women only and 1% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Schizophrenia Spectrum and Other Psychotic Disorders studies take
Of 27 interventional studies with no phase under Schizophrenia Spectrum and Other Psychotic Disorders, half reached primary completion within 41 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Interventional, no phase | 41 mo26–59 · 27 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 84. Browse all 84 → or search them.
- An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease PsychosisEnrolling by invitationNCT07459660Phase 23 countries
- A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRecruitingNCT06887192Phase 215 countries
- SloMo2: Implementation, Effectiveness, and Cost-effectiveness StudyRecruitingNCT06568081Not applicable1 country
- Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in SchizophreniaRecruitingNCT066739661 country
- Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine ApproachNot yet recruitingNCT07152184Phase 2
- REFLECT: A Novel Group-Based Compassion-Focussed Cognitive Behavioural Approach to Core Beliefs in PsychosisRecruitingNCT07569471Not applicable1 country
- Biomarkers/Biotypes, Course of Early Psychosis and Specialty ServicesRecruitingNCT067403831 country
- Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use DisorderRecruitingNCT06939088Phase 21 country
- Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care ClinicRecruitingNCT06624462Not applicable1 country
- Karolinska Schizophrenia ProjectRecruitingNCT068724631 country
- Sex, Psychopharmacology, and DiabetesRecruitingNCT05951660Not applicable1 country
- The Personalized Psychological Treatment for PsychosisNot yet recruitingNCT06603922Not applicable5 countries
- VR-based Avatar Therapy for Treatment of Auditory HallucinationsRecruitingNCT06505564Not applicable3 countries
- Cigarette Consumption After switchinG to High or Low Nicotine strENght E-cigaretteS In Smokers With SchizophreniaRecruitingNCT04452175Not applicable1 country
- A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With SchizophreniaTerminatedNCT05443724Phase 25 countries
- EPI-MINN: Targeting Cognition and Motivation - NationalActive, not recruitingNCT05877716Not applicable1 country
- OnTrackNY's Learning Healthcare SystemSuspendedNCT040217191 country
- An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)CompletedNCT03055338Phase 21 country
- A Randomized Controlled Trial With Rituximab for Psychotic Disorder in AdultsActive, not recruitingNCT05622201Phase 21 country
- Early Psychosis Intervention - Spreading Evidence-based TreatmentCompletedNCT03919760Not applicable1 country
- ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis InterventionCompletedNCT04298450Not applicable1 country
- Repetitive TMS & Cognitive Training in Adults With SchizophreniaTerminatedNCT03741751Not applicable1 country
- State Representation in Early Psychosis - Project 4CompletedNCT05664594Not applicable1 country
- A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaCompletedNCT05227703Phase 23 countries
- Remote State Representation in Early PsychosisCompletedNCT05538832Early Phase 11 country
- State Representation in Early PsychosisCompletedNCT052731641 country
- A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaCompletedNCT05227690Phase 22 countries
- Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)CompletedNCT03983018Phase 21 country
- Plan D- Vitamin D Supplementation in Psychotic DisordersCompletedNCT05211635Not applicable1 country
- Music Therapy Advocacy Recording Intervention (MTAR) on Internalized StigmaTerminatedNCT05723328Not applicable1 country
- Acceptance and Commitment Therapy-based Lifestyle Counselling Programme for Early Psychosis on Physical ActivityCompletedNCT04916496Not applicable1 country
- Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum DisordersStatus unknownNCT06423651Not applicable1 country
- Efficacy of Prebiotic and Probiotic Dietary Modulation in Schizophrenic DisordersCompletedNCT04366401Not applicable1 country
- Biomarkers of Conversion Risk and Treatment Response in Early-Stage SchizophreniaCompletedNCT03323437Phase 41 country
- Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT05321602Phase 11 country
- Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind)CompletedNCT03309475Not applicable1 country
- Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic PatientsCompletedNCT060409441 country
- Community Reinforcement Approach and Family Training for Substance Use in Early Psychosis InterventionCompletedNCT05300633Not applicable1 country
- Randomized Controlled Trial of Pyridoxine for Tardive DyskinesiaCompletedNCT03287778Not applicable1 country
- Effects of Delta-9-THC and Iomazenil in Healthy HumansCompletedNCT00982982Early Phase 11 country
- Ascertaining Diagnosis Classification With Elicited SpeechCompletedNCT056010631 country
- Mindfulness, Empathy and the Oxytocinergic System in Persons With SchizophreniaStatus unknownNCT05491486Not applicable1 country
- Video Games Among People With SchizophreniaCompletedNCT03133143Not applicable1 country
- Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy ParticipantsCompletedNCT05106309Phase 11 country
- Family Psychoeducation for Adults With Psychotic Disorders in TanzaniaCompletedNCT04013932Not applicable1 country
- Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled TrialCompletedNCT03955549Phase 31 country
- Side Effects of Antipsychotic MedicationsCompletedNCT003631811 country
- One-Year Trial Of Oral Ziprasidone In Patients With Metabolic SyndromeTerminatedNCT00748566Phase 41 country
- Compensatory Cognitive Training in Clinical High Risk Latino YouthStatus unknownNCT02245607Not applicable2 countries
- Berberine as Adjuvant Treatment for Schizophrenia PatientsCompletedNCT02983188Phase 2/31 country